The QualityStocks Daily Thursday, June 26th, 2025

Today's Top 3 Investment Newsletters

360 Wall Street(CYN) $13.6000 +171.46%

QualityStocks(ASTI) $2.8400 +143.78%

InsiderTrades(LIVE) $15.7000 +85.80%

The QualityStocks Daily Stock List

Ascent Solar Technologies (ASTI)

Profitable Trader Authority, Small Cap Firm, QualityStocks, StockEarnings, OTCPicks, Investor Ideas, PennyStocks24, Top Stock Picks, Alternative Energy, StreetInsider, StockEgg, SmarTrend Newsletters, PennyTrader Publisher, The Street, CRWEWallStreet, StockHotTips, PennyOmega, DrStockPick, The Online Investor, CRWEPicks, CRWEFinance, BestOtc, AllPennyStocks, PennyToBuck, PennyStockVille, Promotion Stock Secrets, PennyPro, PennyInvest, Penny Invest, MadPennyStocks, HotOTC, Greenbackers, FeedBlitz, CoolPennyStocks, BUYINS.NET, BullRally, InvestorPlace, Stock Rocket Report, StockRich, Stocks That Move, SmallCapVoice, Street Insider, TopPennyStockMovers, StockOodles, Premium Stock Alerts, InvestorsUnderground, InvestorSoup, StocksEarning, SuperStockHunter, DSR News, SuperStockTips, The Stock Detective, TheStockWizards.net, TopStockAnalysts, TradingMarkets, Wall Street Resources, Beacon Equity Research, WealthMakers, Winston Small Cap, The Momentum Traders Network, Penny Stocks Finder, ProTrader, Wise Alerts, Shah's Insights & Indictments, 360 Wall Street, PHUB News, Smartmoneytrading, Stock Market Authority, Stock News Now, Lebed.biz, Stock Specialists, MarketBeat, Penny Stock Pinnacle, Penny Stock Craze, Stockgoodies, PCG Advisory, StockMister, Momentum Traders, Mega Stock Picks, Rick Saddler and Stock Preacher reported earlier on Ascent Solar Technologies (ASTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ascent Solar Technologies Inc. (NASDAQ: ASTI) (FRA: A8M) is a company focused on designing, manufacturing and selling copper-indium-gallium-diselenide photovolta-ic products for aerospace, defense emergency management and consumer/OEM appli-cations.

The firm has its headquarters in Thornton, Colorado and was incorporated in 2005, on October 18th by Joseph H. Armstrong and Mohan S. Misra. It operates as part of the solar industry, under the technology sector. The firm serves consumers across the globe.

The company’s technology represents the cutting edge of flexible power which can be directly integrated into consumer products and off-grid applications, as well as other aerospace applications. Its production facility is located in Thornton, Colorado.

The enterprise is focused on integrating its PV products into high value markets, such as aerospace, satellites, near earth-orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). It also designs and manufactures PV-integrated portable power appli-cations for commercial and military users. The enterprise's products include XD12 USB Solar Charger, XD48 Solar Charger, WS50 Solar Blanket and bare modules. It manufactures its products by affixing a thin CIGS layer to a flexible, plastic substrate using a roll-to-roll process that permits it to fabricate its flexible PV modules in an in-tegrated sequential operation. It uses monolithic integration techniques which enable it to form complete PV modules with inter-cell connections.

The enterprise markets and sells its products through OEMs, system integrators, dis-tributors, retailers, and e-commerce companies.

Ascent Solar Technologies (ASTI), closed Thursday's trading session at $2.84, up 143.7768%, on 112,814,148 volume. The average volume for the last 3 months is 22,610 and the stock's 52-week low/high is $1.1/$12.

Adial Pharmaceuticals (ADIL)

QualityStocks, MarketClub Analysis, StockMarketWatch, BUYINS.NET, TopPennyStockMovers, MarketBeat, InvestorsUnderground, PennyStockProphet, PennyStockScholar, 360wallstreet, Schaeffer's, TradersPro, Small Cap Firm, StreetInsider, The Online Investor, Timothy Sykes and PoliticsAndMyPortfolio reported earlier on Adial Pharmaceuticals (ADIL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical firm that is engaged in developing treatments for preventing or treating addiction and associated disorders.

The firm has its headquarters in Charlottesville, Virginia and was incorporated in November 2010 by Bankole A. Johnson. It operates as part of the pharmaceutical manufacturing industry, under the healthcare sector, in the biotech and pharma sub-industry and serves consumers in Virginia.

The enterprise’s pipeline is made of a selective serotonin-3 antagonist dubbed AD04, which is in-dicated for treating alcohol use disorder. The active ingredient in the formulation, i.e. ondansetron, is the serotonin-3 antagonist. The formulation has also been indicated for the treatment of other ad-dictive disorders including smoking, obesity and opioid use disorder, among other drug addictions. The candidate recently concluded its phase 2b study which tested its effectiveness in treating alco-hol use disorders, and it demonstrated promising results in decreasing the quantity and frequency of heavy drinking and drinking in general, with no noticeable safety concerns. The enterprise also develops AD01, which is indicated for treating addictive behaviors, and recently concluded phase 1 trials. In addition to this, the enterprise is also involved in the development of drug candidates for non-opioid pain alleviation and other disorders and ailments.

The firm is planning to venture into the genetic testing market after receiving a patent for its AD04 candidate, bringing the firm one step closer to helping identify patients that could benefit from their formulation. This move will also allow the firm to commercialize a companion diagnostic test to AD04 in the future, which will help extend its consumer reach and in turn, bring in even more in-vestors.

Adial Pharmaceuticals (ADIL), closed Thursday's trading session at $0.4698, up 90.9756%, on 282,428,495 volume. The average volume for the last 3 months is 9,787,516 and the stock's 52-week low/high is $0.22/$3.

Sonim Technologies (SONM)

StockEarnings, QualityStocks, MarketBeat, StocksEarning, StockMarketWatch, The Stock Dork, StockRockandRoll, PennyStockLocks, Penny Stock 101, The Online Investor, PennyStocksUnited and InvestorPlace reported earlier on Sonim Technologies (SONM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonim Technologies Inc. (NASDAQ: SONM) (FRA: 2W9) is engaged in the provision of rugged-ized mobile accessories and phones for task workers.

The firm is based in Austin, Texas and was incorporated in 1999 on August 5th by Joakin Wiklund, Sudu Srinivasan, Jai Kumar, Anush Gopalan, Isaac Eteminan and Ram Chandran. Prior to its name change in December 2001, the firm was known as NaviSpin.com Inc.

The company provides solutions in 3 categories namely, cloud-based software and application ser-vices; industrial-grade accessories; and, ultra-rugged mobile devices. It sells accessories, barcode scanners and ruggedized phones through distribution channels in Europe, South America and North America and sells its accessories and mobile phones primarily to wireless carriers in Canada and the U.S. It serves defense, agriculture, transportation, utilities, oil and gas, security and con-struction industries across the globe.

Its products include a portable communications system dubbed the Rapid Deployment Kit; hands-free in-vehicle voice communication solution, multi-bay charging accessories and remote speaker microphones, which are all industrial grade accessories and the Sonim XP3, XP5s and XP8, which are all based on the android platform and can attach to private and public wireless networks. The enterprise also offers SmartScanner products like an android-based tablet called Sonim RS80 and an LTE device that’s android-based called Sonim RS60.

Sonim Technologies (SONM), closed Thursday's trading session at $1.76, up 39.6825%, on 31,074,689 volume. The average volume for the last 3 months is 6,556,795 and the stock's 52-week low/high is $0.85/$10.5.

Epsilon Energy (EPSN)

InsiderTrades, The Online Investor, Kiplinger Today, TradersPro, InvestorPlace, Zacks, Smart Investing Society and MarketBeat reported earlier on Epsilon Energy (EPSN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Epsilon Energy Limited (NASDAQ: EPSN)

The firm has its headquarters in Calgary, Canada and was incorporated in 2005, on March 14th by John K. Wilson and Zoran Arandjelovic. It operates as part of the oil and gas E&P industry, un-der the energy sector. Epsilon Energy mainly serves consumers in North America.

The enterprise operates through the Upstream, Gathering System, and Corporate segments. The Upstream segment focuses on the acquisition, exploration, development, and production of oil and natural gas reserves on properties within the U.S. The Gathering System segment focuses on partnering with two other companies to operate a natural gas gathering system. It holds leasehold rights to approximately 102,506 gross (23,602 net) acres. The enterprise has natural gas produc-tion in the Marcellus Shale in Pennsylvania, oil, natural gas liquids and natural gas production in the Permian Basin in Texas and New Mexico and in the Anadarko Basin in Oklahoma. On the other hand, the Corporate segment is involved in corporate and governance functions.Epsilon Energy generates revenue from the sale of crude oil and natural gas. Its subsidiaries include Dewey Energy Holdings LLC, Epsilon Energy USA Inc., Altolisa Holdings LLC, and Epsilon Midstream LLC.

Epsilon Energy (EPSN), closed Thursday's trading session at $7.81, up 1.6927%, on 196,297 volume. The average volume for the last 3 months is 659,125 and the stock's 52-week low/high is $4.95/$8.5.

Momo Inc. (MOMO)

QualityStocks, StocksEarning, StockEarnings, MarketClub Analysis, InvestorPlace, Schaeffer's, ChineseWire, BillionDollarClub, Marketbeat, Market Intelligence Center Alert, Zacks, The Street, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, FreeRealTime, The Street Report, Marketbeat.com, The Online Investor, BUYINS.NET, INO.com Market Report, TopStockAnalysts, TipRanks, Louis Navellier, Trading Concepts, Wealth Insider Alert, StreetAuthority Daily, TradersPro, Investopedia, Greenbackers, DividendStocks, Daily Wealth, PennyDoctor, Money Morning, StockMarketWatch, StocksImpossible, Street Insider, ChartAdvisor, Early Bird, Earnings360, First Penny Picks, Barchart, CrashTrade, Investing Signal, InvestmentHouse, Jason Bond, AskSlapper, Orbit Stocks, OTCBB Journal, Profit Confidential, Promotion Stock Secrets, Short Term Wealth, Terry's Tips, The Best Newsletters, The Stock Dork and One Hot Stock reported earlier on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent global survey reveals that social media has become the leading source of news for most Americans, surpassing traditional platforms like television and news websites. According to the Reuters Institute’s Digital News Report, 54% of U.S. participants said they turn to social platforms such as Facebook, YouTube, and X for news updates. This figure is higher than those who get their news from TV (50%) or from dedicated news websites and apps (48%).

This signals a significant shift in how people engage with news content. Instead of depending solely on major news outlets, many are now gravitating toward content shared by influencers and digital personalities. One prominent example is Joe Rogan, whose commentary reached about 22% of Americans in a single week.

While this transition offers greater accessibility, it also raises valid concerns. The increasing popularity of news delivered by individuals rather than institutions has contributed to the spread of misinformation. The study noted that nearly half of global respondents (47%) view online influencers as key sources of misleading or false information, placing them on par with politicians in terms of mistrust.

The report also highlights a growing pattern among public figures and politicians who now prefer giving interviews to online personalities or partisan creators instead of established journalists. This move often results in softer interviews and less accountability, giving these figures more control over the narrative without facing difficult questions.

Changes in how people use X were also evident, particularly after Elon Musk’s acquisition of the platform in 2022. There’s been a marked increase in usage among right-leaning individuals, especially young men, while more liberal users have decreased their activity. In fact, in the U.S., the number of self-identified right-wing users on X has tripled, with the UK seeing almost double the amount.

Meanwhile, competing platforms like Threads, Bluesky, and Mastodon have yet to gain significant traction in the news space, with each capturing less than 2% of global users.

TikTok is rapidly becoming a major player in news delivery, now used by 17% of people worldwide for news, up 4% from the previous year. Additionally, AI chatbots are becoming a growing source of news for younger audiences, especially those under 25. Still, many users worry that AI could lead to less transparency and accuracy in reporting.

Despite the growing popularity of alternative sources, the study suggests that trust in long-standing news brands remains strong, even if they’re not used as frequently as before.

As digital media continues to evolve, the challenge remains: choosing who to trust in an increasingly noisy information landscape. As social media actors like Momo Inc. (NASDAQ: MOMO) jostle for dominance in this space, that is a key question they will have at the back of their minds as they tweak their strategies going forward.

Momo Inc. (MOMO), closed Thursday's trading session at $8.75, up 2.6995%, on 1,569,251 volume. The average volume for the last 3 months is 95,860 and the stock's 52-week low/high is $5.0456/$8.8254.

Energy Fuels (UUUU)

QualityStocks, SmallCapRelations, NetworkNewsWire, MissionIR, SeriousTraders, MiningNewsWire, InvestorBrandNetwork, Tiny Gems, Stocks to Buy Now, Tip.us, StocksToBuyNow, BillionDollarClub, Green Energy Stocks, SmallCapSociety, Rocks & Stocks, TinyGems, MarketClub Analysis, RedChip, Streetwise Reports, Schaeffer's, MarketBeat, TradersPro, InvestorPlace, Top Pros' Top Picks, Zacks, InvestorIntel, FreeRealTime, INO Market Report, Kiplinger Today, Trades Of The Day, Early Bird, StockMarketWatch, Broad Street, BUYINS.NET, Daily Trade Alert, Dynamic Wealth Report, StreetInsider, InvestorsObserver Team, Green Chip Stocks, Investors Alley, Money Wealth Matters, Investment House, Investopedia, Investor News, Money and Markets and FutureMoneyTrends.com reported earlier on Energy Fuels (UUUU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) announced that the Government of Victoria, Australia has approved the Work Plan for the Donald Rare Earth and Mineral Sand Project, marking the final major regulatory milestone needed to proceed with construction and operation. The joint venture with Astron Corporation allows Energy Fuels to earn up to a 49% stake through a combined US$136.5 million investment. The project will supply rare earth mineral concentrates for processing at the company’s White Mesa Mill in Utah, supporting U.S. production of key elements such as neodymium-praseodymium, terbium, and dysprosium.

To view the full press release, visit https://ibn.fm/oIXet

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based critical minerals company, focused on uranium, rare earth elements (“REEs”), heavy mineral sands (“HMS”), vanadium and medical isotopes. The company has been the leading U.S. producer of natural uranium concentrate for the past several years, which is sold to nuclear utilities that process it further for the production of carbon-free nuclear energy, and owns and operates several conventional and in siturecovery uranium projects in the western United States. Energy Fuels also owns the White Mesa Mill in Utah, which is the only fully licensed and operating conventional uranium processing facility in the United States. At the mill, the company also produces advanced REE products and vanadium oxide (when market conditions warrant), and is preparing to begin pilot-scale recovery of certain medical isotopes from existing uranium process streams needed for emerging cancer treatments. The company also owns the operating Kwale HMS project in Kenya, which is nearing the end of its life, and is developing three additional HMS projects, including the Toliara Project in Madagascar, the Bahia Project in Brazil and the Donald Project in Australia, in which Energy Fuels has the right to earn up to a 49% interest in a joint venture with Astron Corporation Limited. The company is based in Lakewood, Colorado, with its heavy-mineral sands operations managed from Perth, Australia. For more information, visit the company’s website at www.EnergyFuels.com .

Energy Fuels (UUUU), closed Thursday's trading session at $5.9, up 5.1693%, on 12,029,750 volume. The average volume for the last 3 months is 12,351,720 and the stock's 52-week low/high is $3.2/$7.47.

SNDL Inc. (SNDL)

StockEarnings, QualityStocks, Schaeffer's, InvestorPlace, CannabisNewsWire, StocksEarning, MarketBeat, Trades Of The Day, BUYINS.NET, Daily Trade Alert, The Street, Kiplinger Today, StreetInsider, FreeRealTime, The Online Investor, Early Bird, TheoTrade, Prism MarketView, CNBC Breaking News, Investopedia, MarketClub Analysis, StockMarketWatch and MarketClub reported earlier on SNDL Inc. (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Texas Governor Greg Abbott has vetoed a measure that aimed at banning all consumable THC products in the state. The move keeps the growing market of THC gummies, vape cartridges, and similar goods open for business. Abbott issued the veto just before the deadline, preventing what would have been one of the strictest THC bans nationwide. 

Abbott called on lawmakers to craft tighter regulations for THC products rather than imposing an outright ban. The bill, Senate Bill 3, would have made it a criminal offense to produce, sell, or possess any THC consumables. 

The bill followed ongoing efforts in various states to crack down on THC, particularly after the 2018 Farm Bill gave states the power to regulate hemp. Hemp, though non-intoxicating in its natural form, can be synthetically altered to produce THC. 

Abbott had not publicly weighed in on the matter while the bill was moving through the legislature, leaving many uncertain about his stance. He explained that the bill likely wouldn’t survive a constitutional test and would clash with existing state and federal laws. He added that pursuing a law destined to be struck down would only delay real solutions to concerns about public safety tied to THC products. 

The veto sparked immediate backlash, especially from Lieutenant Gov. Dan Patrick, who had championed the legislation. Patrick had made the THC ban a top priority and had even threatened to push for a special legislative session if it didn’t pass. In a strongly worded statement on social media, Patrick expressed disappointment, citing overwhelming support among Republican lawmakers, law enforcement, educators, and families affected by substance abuse. 

Instead of a ban, Abbott is encouraging lawmakers to treat THC products like alcohol—enforcing age restrictions and limiting marketing aimed at minors. Patrick, meanwhile, has planned a press event in Austin to further address the matter. 

The legal gray areas in current laws have allowed a thriving THC market to develop, even in states where cannabis remains illegal. Texas has some of the toughest anti-cannabis laws in the U.S., banning recreational use entirely and offering only limited medical access. The hemp industry, however, has created a way for Texans to legally obtain products that offer similar effects to cannabis. 

Republican legislators have voiced concerns over the safety of these products, especially given the lack of consistent federal guidelines on manufacturing practices. While Texas has pursued one of the more aggressive approaches to curbing THC sales, other states like California have focused instead on age restrictions and potency limits. 

Florida Governor Ron DeSantis vetoed a similar measure last year, stating that it would negatively affect small businesses. 

Opponents of the Texas legislation argue that the products provide vital relief for individuals unable to qualify for the state’s narrow medical cannabis program. Business owners across the state also stress that the sector supports thousands of jobs and generates significant revenue. 

The marijuana industry, including major brands like SNDL Inc. (NASDAQ: SNDL), hopes that more U.S. jurisdictions that still implement prohibitionist policies against cannabis rethink their stance and create legal markets for the substance so that jobs, state revenue and general livelihoods can be boosted by the legal marijuana business ecosystem. 

SNDL Inc. (SNDL), closed Thursday's trading session at $1.25, up 2.459%, on 1,032,997 volume. The average volume for the last 3 months is 212,143,639 and the stock's 52-week low/high is $1.22/$2.4.

Quantum BioPharma (QNTM)

QualityStocks, SmallCapRelations, BioMedWire, InvestorBrandNetwork, MissionIR, SeriousTraders, Stocks to Buy Now, TechMediaWire, Tiny Gems, StocksToBuyNow, Tip.Us, NetworkNewsWire, TinyGems, SmallCapSociety, StockWireNews, Fierce Analyst, 360 Wall Street, Premium Stock Alerts and Timothy Sykes reported earlier on Quantum BioPharma (QNTM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quantum BioPharma (NASDAQ: QNTM) a biopharma company focused on biotech innovation, announced that portfolio company Unbuzzd Wellness Inc. has partnered with MZ Digital and Dealmaker to raise up to $5 million through a Regulation D 506(c) offering. Unbuzzd, the maker of unbuzzd(TM)—a beverage designed to speed alcohol metabolism and reduce hangover symptoms—plans to use the funds to expand its direct-to-consumer, retail, and distributor reach. Led by CEO John Duffy, a former Coca-Cola executive, and advised by Celsius Holdings’ ex-CEO Gerry David, the company sees this raise as a step toward a future IPO.

To view the full press release, visit https://ibn.fm/t7BCB

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD(TM) and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com . The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma (QNTM), closed Thursday's trading session at $21.12, off by 13.3361%, on 410,378 volume. The average volume for the last 3 months is 10,491,448 and the stock's 52-week low/high is $2.7/$38.25.

BitFuFu Inc. (FUFU)

CryptoCurrencyWire, QualityStocks, TradersPro, MarketBeat and 360 Wall Street reported earlier on BitFuFu Inc. (FUFU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bitcoin took a hard hit over the weekend, dipping to its lowest value since May as global tensions and inflation concerns shook investor confidence. The decline was part of a wider slump in digital currencies, with the entire crypto market reacting swiftly to escalating geopolitical risks.

On Sunday, Bitcoin slipped beneath the $99,000 threshold for the first time in over a month. Ether also took a hit, plunging more than 10%. Other major digital currencies, including dogecoin, Solana, and XRP followed suit, all experiencing significant drops that pulled the crypto sector broadly into the red.

There was a modest rebound later in the day. Bitcoin had recovered some ground, trading just below $101,000, down about 1% over the last 24 hours. Ether had also recouped a portion of its earlier losses, sitting at around $2,200, down 2.5%.

The sudden crash seems to have been triggered by both geopolitical uncertainty and growing anxiety over inflation. Reports surfaced that Iran might attempt to shut down the Strait of Hormuz, a crucial channel responsible for transporting close to a fifth of the world’s oil. According to JPMorgan, a complete shutdown could send oil prices soaring to $130 per barrel.

Such a spike in oil costs could reignite inflation in the United States, possibly pushing it back to 5 percent—a level last seen in March 2023 when the Federal Reserve was still increasing interest rates. That prospect has caused traders to reconsider the likely trajectory of rate cuts, shifting capital away from riskier investments like cryptocurrencies.

Although Bitcoin is often marketed as a hedge against inflation, its recent performance suggests it’s acting more like a volatile tech stock than a safe store of value. Data from crypto analytics firm Kaiko reveals that Bitcoin’s connection to Nasdaq has grown significantly over the past few weeks, reversing the disconnect seen earlier this year during a period of heavy investment into Bitcoin spot ETFs.

Institutional investor behavior has also shifted. Between Monday and Wednesday last week, Bitcoin spot ETFs saw over $1 billion in inflows. But that momentum stalled, and by Thursday, net inflows had flatlined. Friday saw a modest $6.4 million added—just as President Donald Trump left the G7 summit early and the U.S. announced a two-week analysis of its Iran policy.

Technical factors further worsened the sell-off. Bitcoin’s dip below $99,000 triggered automatic liquidations across major offshore trading platforms like Bybit and Binance. In just 24 hours, over $1 billion in cryptocurrency positions were wiped out, most of them long positions, highlighting how unprepared the market was for the weekend downturn.

It remains to be seen how the recent volatility in the crypto market will impact the forecasts of industry players like BitFuFu Inc. (NASDAQ: FUFU) over the coming months.

BitFuFu Inc. (FUFU), closed Thursday's trading session at $3.15, off by 0.6309148%, on 402,780 volume. The average volume for the last 3 months is 175,562 and the stock's 52-week low/high is $2.91/$6.33.

Scinai Immunotherapeutics (SCNI)

SmallCapRelations, BioMedWire, QualityStocks, SeriousTraders, InvestorBrandNetwork, MissionIR, Tiny Gems, Stocks to Buy Now, Tip.us, StocksToBuyNow, SmallCapSociety, NetworkNewsWire, MarketClub Analysis, 360 Wall Street, Premium Stock Alerts and Schaeffer's reported earlier on Scinai Immunotherapeutics (SCNI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the “Oscar of Italian Dermatology” from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title “Blocking soluble Fas Ligand ameliorates pemphigus” , confirms PC111’s ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris. Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its potential as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions.

To view the full press release, visit https://ibn.fm/51v14

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com .

Scinai Immunotherapeutics (SCNI), closed Thursday's trading session at $2.47, off by 1.9841%, on 36,754 volume. The average volume for the last 3 months is 322,930 and the stock's 52-week low/high is $1.9/$8.92.

Annovis Bio (ANVS)

BioMedWire, QualityStocks, SmallCapRelations, MissionIR, SeriousTraders, InvestorBrandNetwork, Stocks to Buy Now, Tip.us, NetworkNewsWire, StocksToBuyNow, SmallCapSociety, RedChip, TradersPro, Schaeffer's, MarketBeat, MarketClub Analysis, The Wealth Report, InvestorPlace, Red Chip, BUYINS.NET, INO Market Report, FreeRealTime, Daily Trade Alert, Mega Stock Alerts, OTCtipReporter, Penny Pick Finders, PennyStockProphet, 360 Wall Street, Profitable Trader Authority, Zacks, StockMarketWatch, StockOnion, StreetInsider, The Online Investor, Timothy Sykes and PennyStockScholar reported earlier on Annovis Bio (ANVS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Annovis Bio (NYSE: ANVS) , a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different drug formulations in both animals and humans.

To view the full press release, visit https://ibn.fm/w0fFP

About Annovis Bio Inc.

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn , X and YouTube .

Annovis Bio (ANVS), closed Thursday's trading session at $2.17, off by 5.2402%, on 725,061 volume. The average volume for the last 3 months is 1,179,957 and the stock's 52-week low/high is $1.11/$17.88.

Aditxt (ADTX)

QualityStocks, SmallCapRelations, SeriousTraders, InvestorBrandNetwork, Stocks to Buy Now, Tiny Gems, MissionIR, StocksToBuyNow, Tip.us, BioMedWire, NetworkNewsWire, SmallCapSociety, TinyGems, Premium Stock Alerts, BUYINS.NET, 360 Wall Street, Schaeffer's, MarketClub Analysis, FreeRealTime, MarketBeat, PennyStockProphet, PennyStockScholar, RedChip, PCG Advisory, OTCtipReporter, Penny Pick Finders, StockOnion, HotOTC, StreetInsider, Buzz Stocks, The Stock Dork, Timothy Sykes and Profitable Trader Authority reported earlier on Aditxt (ADTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aditxt (NASDAQ: ADTX) , a social innovation platform advancing health breakthroughs, announced that Co-founder and CEO Amro Albanna will present at the NEXT SUPER STOCK livestream hosted by Wall Street Reporter on June 26, 2025, at 1:00 p.m. ET. Albanna will outline Aditxt’s innovation acceleration model, provide updates on its autoimmunity and early cancer detection programs, and share the latest on the company’s pending acquisition of Evofem Biosciences, Inc.

To view the full press release, visit https://ibn.fm/3P85m

About Aditxt Inc.

Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) , which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit www.Aditxt.com .

Aditxt (ADTX), closed Thursday's trading session at $1.56, off by 4.2945%, on 2,126,112 volume. The average volume for the last 3 months is 309,999 and the stock's 52-week low/high is $1.28/$27200.

The QualityStocks Company Corner

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings (NASDAQ: BREA) , an Ireland-based company executing a multi-club ownership strategy in global football, announced that its portfolio club S.S. Juve Stabia recorded the highest market value increase in Italy's Serie B for the 2024–25 season. According to Virgilio Sport, the club's valuation rose 245% to US$32 million, driven by a strong on-field performance and promotion playoff run. Brera finalized its 52% controlling stake in Juve Stabia on June 20, 2025, following FIGC approval. Executive Chairman Daniel McClory credited the growth to Brera's operational and player development strategy.

To view the full press release, visit https://nnw.fm/gnyYl

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Additional Resources

Brera Holdings PLC (NASDAQ: BREA), closed Thursday's trading session at $6.7619, up 909.2388%, on 54 volume. The average volume for the last 3 months is 15,947 and the stock's 52-week low/high is $4.999/$19.5.

Recent News

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) , via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC, a top interventional psychiatry clinic founded by Dr. Rebecca Cohen in the Sarasota-Bradenton region. The clinic offers advanced treatments for suicidal depression, PTSD, and CNS disorders, including ketamine, Spravato, and TMS. The deal aims to establish a foundational clinic for HOPE's regional growth and reflects its mission to deliver compassionate, evidence-based mental health care. Final terms remain subject to closing and definitive agreements.

To view the full press release, visit https://ibn.fm/0cNgG

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

  • NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
  • NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
  • Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

Investment Considerations
  • NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting significant unmet needs in central nervous system disorders.
  • The company’s lead candidate, NRX-101, has received FDA Breakthrough Therapy designation, expediting its development.
  • NRX-100 (preservative free IV ketamine) has been granted Fast Track designation by the FDA for acute suicidal depression a patent for this novel formulation has been filed with the US Patent and Trademark Office.
  • HOPE Therapeutics, NRx’s interventional psychiatry subsidiary, is targeting $100M in revenue by year-end 2025 through a national clinic network treating suicidal depression and PTSD.
  • The company’s experienced leadership team has a proven track record in pharmaceutical development and commercialization.
  • NRx is positioned to address large and growing markets with its novel depression treatments, non-opioid therapeutic solutions and directly help patients in HOPE clinics.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Thursday's trading session at $3.5, up 7.0336%, on 1,954 volume. The average volume for the last 3 months is 327,038 and the stock's 52-week low/high is $1.1/$6.01.

Recent News

Lantern Pharma Inc. (NASDAQ: LTRN)

The QualityStocks Daily Newsletter would like to spotlight Lantern Pharma Inc. (NASDAQ: LTRN).

Lantern Pharma uses a proprietary AI platform, RADR ® , to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data.

A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population.

The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually.

Lantern Pharma (NASDAQ: LTRN) , a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, recently reported an encouraging clinical outcome in its Phase 2 HARMONIC(TM) trial, where a patient with advanced non-small cell lung cancer ("NSCLC") achieved a complete response using LP-300, a compound optimized through Lantern's AI-powered platform, RADR(R) ( https://ibn.fm/II6O6 ).

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR® platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic™) for non-small cell lung cancer (NSCLC) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (TNBC), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

  • LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
  • LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
  • LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
  • CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

Investment Considerations
  • Lantern Pharma’s AI-driven RADR® platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline.
  • The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL.
  • Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations.
  • Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways.
  • With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support pipeline advancement and platform development.

Lantern Pharma Inc. (NASDAQ: LTRN), closed Thursday's trading session at $3.14, up 0.9646302%, on 164 volume. The average volume for the last 3 months is 59,035 and the stock's 52-week low/high is $2.55/$6.118.

Recent News

BluSky AI Inc. (OTC: BSAI)

The QualityStocks Daily Newsletter would like to spotlight BluSky AI Inc. (OTC: BSAI).

BluSky AI (OTC: BSAI) , a developer of modular, GPU-centric data center infrastructure, has engaged IBN to lead its corporate communications. BluSky's scalable SkyMod data centers are built off-site and optimized for AI workloads, offering rapid deployment, advanced cooling, and compatibility with renewable energy. As AI demand surges across North America, BluSky aims to fill a key infrastructure gap with fast, cost-effective compute capacity. IBN will drive outreach through its extensive investor network and media platforms.

To view the full press release, visit https://ibn.fm/jG4f1

BluSky AI Inc. (OTC: BSAI) is pioneering the next generation of AI infrastructure through modular, rapidly deployable data centers that meet the escalating compute demands of artificial intelligence, machine learning, and high-performance computing. The company’s mission is to empower AI innovators by eliminating infrastructure bottlenecks and accelerating time-to-compute with energy-efficient, scalable solutions.

Rather than betting on individual AI applications, BluSky AI addresses the universal need for compute power—positioning itself as a foundational layer in the AI revolution. Its infrastructure-first approach enables clients to focus on innovation while the company delivers the critical backbone powering tomorrow’s breakthroughs.

BluSky AI is headquartered in Salt Lake City, Utah.

Products

BluSky AI’s core offering is its SkyMod series of modular data centers—pre-assembled, scalable compute units designed specifically for AI workloads. The flagship SkyMod One delivers 1 MW of compute power in a compact 1,400-square-foot footprint, while the SkyMod XL offers 1.7 MW in 3,000 square feet. These units are fully assembled off-site, tested, and shipped ready for plug-and-play deployment either on BluSky-owned land or client facilities.

SkyMod modules integrate NVIDIA GPUs and are optimized for high-density AI applications such as generative AI, large language models, inference engines, and scientific computing. Built for rapid scaling and high efficiency, each system includes advanced cooling, secure infrastructure, and dynamic workload balancing to support evolving client needs.

The company’s data centers are engineered for sustainability, incorporating renewable energy sources like solar, wind, and geothermal where available. By deploying on powered land assets, BluSky AI shortens lead times and lowers costs, creating a fast, flexible alternative to traditional monolithic data centers.

Market Opportunity

The global data center market was valued at $347.6 billion in 2024 and is projected to reach $652.0 billion by 2030, growing at a CAGR of 11.2%, driven by the rapid expansion of AI, machine learning, and IoT adoption, according to Grand View Research. As enterprises demand faster, more scalable compute solutions, modular infrastructure like BluSky AI’s SkyMod series offers a compelling alternative to legacy data center models.

With North America accounting for over 40% of the global market and the U.S. expected to grow at a 10.7% CAGR from 2025 to 2030, BluSky AI is well-positioned to capture demand for AI-optimized infrastructure that can be deployed rapidly and cost-effectively. By focusing on GPU-centric, modular deployments tied to energy infrastructure, the company addresses a growing gap between compute demand and deployment speed in the AI era.

Leadership Team

Trent D’Ambrosio, Chief Executive Officer, is a seasoned executive with a track record in telecommunications, hedge fund management, and natural resource development. He previously sold the first transatlantic fiber cable, built a successful gold mining company, and now leads BluSky AI with a vision to revolutionize AI infrastructure through strategic energy integration and rapid deployment.

Julien Bedard, Chief Technology Officer, is a pioneering technologist known for launching the first Bitcoin escrow and anti-fraud service. At BluSky AI, he oversees cloud architecture, cybersecurity, infrastructure automation, and the development of AI-native data center technology, ensuring scalability and resilience across deployments.

Dan Gay, Chief Operating Officer, has Fortune 500 executive leadership in telecom, technology, and energy, as well as start-up experience with finance and blockchain companies. At MCI and Qwest, he launched new service and sales centers, and directed National Account Sales. He has been a successful CMO in brand creation, product development, partnerships, and revenue generation programs to expand company awareness, sales, and revenue.

Investment Considerations
  • BluSky AI delivers mission-critical infrastructure supporting AI, ML, and HPC applications.
  • SkyMod modules are prefabricated, scalable, and optimized for rapid plug-and-play deployment.
  • The company’s data center designs emphasize sustainability with support for renewable energy.
  • BluSky’s infrastructure-first model addresses universal AI compute needs across industries.
  • A veteran leadership team combines expertise in telecom, finance, and advanced technologies.

BluSky AI Inc. (OTC: BSAI), closed Thursday's trading session at $2.9, up 75.7576%, on 6,769 volume. The average volume for the last 3 months is 5,850 and the stock's 52-week low/high is $0.118/$5.49.

Recent News

Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG)

The QualityStocks Daily Newsletter would like to spotlight Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG).

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is well positioned as platinum and palladium prices have gained considerable momentum in recent weeks, driven largely by a resurgence in demand from China's jewelry sector and increasing concern over global supply constraints. "With a strong asset base and an advanced development project in South Africa, the company is pursuing a strategic path toward becoming an important supplier in a resurging PGM market," reads an article discussing the company. "Platinum Group Metals is making meaningful strides through its flagship Waterberg Project, a large-scale palladium-dominant deposit located on the Northern Limb of South Africa's renowned Bushveld Igneous Complex. The company holds an effective 50.16% interest in the project, which is joint ventured with industry heavyweights Impala Platinum Holdings Limited (‘Implats'), Hanwa Co. Ltd. and the Japan Organization for Metals and Energy Security (‘JOGMEC')."

To view the full article, visit https://ibn.fm/kZQqP

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) is the operator of the Waterberg Project, a bulk underground platinum group metals (PGM) deposit discovered by Platinum Group in 2011 and located on the Northern Limb of the Bushveld Complex in South Africa. The Waterberg Project is planned as a fully mechanised platinum, palladium, rhodium and gold mine, including by-product copper and nickel production, and is projected to be one of the largest and lowest cost PGM mines globally.

The project is a joint venture between Platinum Group; integrated PGM producer Impala Platinum Holdings Ltd. (OTCQX: IMPUY); Japanese consortium HJ Platinum, which includes trading house Hanwa Co. and the government-backed Japan Organization for Metals and Energy Security (JOGMEC); and local empowerment partner Mnombo Wethu Consultants (Pty) Ltd. Platinum Group has an effective 50.22% interest in the Waterberg Project.

The company’s primary business objective is to advance the Waterberg Project to a development and construction decision. An update to the 2019 Definite Feasibility Study is expected in 2024.

PGMs are essential and precious metals that include platinum, palladium, rhodium, iridium, osmium and ruthenium. These metals are known for their purity, high melting points and unique catalytic properties. They are utilized in a number of industrial processes, technologies and commercial applications and play a critical role in autocatalysis and pollution control in the automotive sector. The bulk of global PGMs are mined in Southern Africa and Russia.

The unique properties of PGMs are being applied to various technologies as possible solutions for more efficient energy generation and storage, which may create new demand for PGMs. The company’s battery technology initiative through Lion Battery Technologies Inc., using platinum and palladium in lithium battery technologies, represents one such new opportunity in the high-profile lithium battery research and innovation field.

Platinum Group Metals Ltd. founded Lion Battery Technologies Inc. in partnership with Anglo American Platinum Ltd. (AMS: JNB) to support the use of palladium and platinum in lithium battery applications. Lion Battery has entered into an agreement with Florida International University to further advance a research program that uses platinum and palladium to unlock the potential of Lithium Sulfur (Li-S) battery chemistries.

Platinum Group is headquartered in Vancouver, B.C., and Johannesburg, South Africa.

Waterberg Project

Platinum Group’s sole material mineral property, the Waterberg Project, is presently in process with pre-construction permitting; engineering work, including road upgrade and traffic studies; finalization of power and water infrastructure design; and construction camp design.

The company’s principal product from the Waterberg Project is planned to be a PGM-bearing concentrate. The concentrate will contain economic amounts of six elements comprising platinum, palladium, rhodium, gold, copper and nickel. The company’s partner in the Waterberg Project, Impala Platinum Holdings, has acquired a right of first refusal to enter into an offtake agreement, on commercial arm’s-length terms, for the smelting and refining of mineral products from the Waterberg Project.

The Waterberg project has proven and estimated reserves of 19.5 million ounces of PGMs and gold. When fully operational, the mine is projected to produce more than 400,000 ounces of PGMs annually during the peak period of steady state production. The life of the mine is projected at 45 years.

South Africa’s PGM mining sector remains closely tied to economic developments in the global automotive industry, which in 2022 accounted for approximately 43% of the total global demand for platinum and 82% of the total global demand for palladium.

Market Opportunity

According to a report from Straits Research, a global market and business research firm, the worldwide platinum market had an estimated value of $7.72 billion in 2022 and is projected to reach $11.95 billion by 2031. That represents a CAGR of 5.13% over the forecast period.

Platinum, one of the rarest of precious metals, is about 30 times scarcer than gold. It is crucial to the automotive and electronics industries and is also used to make jewelry. Stricter emissions regulations around the world have led to an increased demand for platinum to be used in catalytic converters to reduce automotive emission, the report states.

A report from Allied Market Research estimated the global palladium market at $16.3 billion in 2021 and projects the market will reach $28.6 billion by 2031, growing at a CAGR of 5.8% over the period.

Palladium is also used in automotive catalytic converters for reducing emissions and in jewelry, dentistry, watchmaking, blood sugar test strips, aircraft spark plugs, surgical instruments, electrical contacts and musical instruments.

An increase in demand for consumer electronics has driven demand for palladium-based multilayer ceramic capacitors (MLCC) used to store energy in electronic devices such as broadcasting equipment, mobile telephones, computers, electronic lighting and high voltage circuits, according to the report.

Management Team

Frank R. Hallam is Co-Founder, Director, President and CEO of Platinum Group. He has over 30 years of experience in the mining, minerals and petroleum industry as an operator, principal and founder. He was a co-founder and former CFO of MAG Silver Corp. He was also co-founder and director of West Timmins Mining Inc. and a director of Lake Shore Gold Corp. In addition, he was CFO and director with gold exploration company Tan Range Exploration Corp. He is a Chartered Professional Accountant and was formerly an auditor in the public mining practice of PwC. He holds a Bachelor of Business Administration from Simon Fraser University.

Greg Blair is CFO of Platinum Group. He has been with Platinum Group since 2010 in various roles, most recently as Interim CFO. Prior to joining Platinum Group, he was at a public accounting firm working on public company (mainly mining) audits. He is a Chartered Professional Accountant and holds a degree in Economics from Simon Fraser University and has completed the Canadian Securities Course.

Kris Begic is VP Corporate Development of Platinum Group. He has over 25 years of experience in the mining industry and capital markets and has been involved with the raising of over $500 million for various exploration and development projects globally. His efforts are focused on project generation, mergers and acquisitions, capital markets, investor relations and marketing.

Platinum Group Metals Ltd. (NYSE American: PLG), closed Thursday's trading session at $1.62, up 5.8824%, on 21,392 volume. The average volume for the last 3 months is 1,618,505 and the stock's 52-week low/high is $0.99/$2.27.

Recent News

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

ESGold (CSE: ESAU) (OTCQB: ESAUF) has closed an oversubscribed non-brokered private placement, raising $3,649,171 through the issuance of nearly 5 million units priced at $0.73 each. The financing, backed by existing and new strategic investors, will fund mill circuit construction, final mobilization at the Montauban gold-silver project, and general working capital. Each unit includes a common share and a warrant exercisable at $0.91 for 18 months. The company also issued 226,863 finder's warrants and paid $165,610 in finder's fees.

To view the full press release, visit https://ibn.fm/afSZ7

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

Investment Considerations
  • Fully Permitted & Funded for Near-Term Production: Construction underway soon at Montauban with gold-silver production expected in Q3 2025.
  • Tailings-to-Cashflow Strategy: Near-term cash flow from processing historic tailings will fund exploration across the district-scale land package.
  • Replicable Clean Mining Model: Scalable approach to legacy mine redevelopment in Canada and globally.
  • Broken Hill Analogue: Geological and structural parallels suggest Montauban may host a larger, mineralized system at depth.
  • Modern 3D Imaging Tech: Cutting-edge ANT survey is producing subsurface imaging beyond 800m, uncovering the potential size of the deposit.

ESGold Corp. (OTCQB: ESAUF), closed Thursday's trading session at $0.87712, up 5.6771%, on 291,261 volume. The average volume for the last 3 months is 257,650 and the stock's 52-week low/high is $0.0221/$0.98.

Recent News

ONAR Holding Corp. (OTCQB: ONAR)

The QualityStocks Daily Newsletter would like to spotlight ONAR Holding Corp. (OTCQB: ONAR).

ONAR's technology-first approach combines its proprietary AI platform with strategic agency acquisitions to deliver measurable marketing results for middle-market companies

Recent board appointment of advertising innovator Jon Bond reinforces ONAR's positioning at the intersection of creativity and technology in the evolving martech landscape

The company's integrated model leverages AI automation across performance media, SEO, and healthcare marketing through its network of agencies

The marketing technology sector finds itself at a crossroads that extends far beyond the typical innovation cycle. As adtech companies scramble to incorporate artificial intelligence into their offerings, launching everything from automated creative platforms to machine learning optimization tools, a critical distinction is emerging between organizations that deploy AI strategically versus those that implement it reactively. The difference lies not in the sophistication of the technology itself, but in how deeply AI capabilities are woven into core business operations. The reality is that most current AI deployments follow a fragmented approach. Companies introduce AI capabilities piecemeal: optimization suggestions in one area, automated reporting in another, predictive analytics as a separate module. While each component may deliver incremental value, this scattered implementation prevents AI from reaching its full potential as a learning system that improves through interconnected data flows. This fragmentation has opened the door for companies that recognize a key market insight: the most valuable implementations are those that create unified intelligence across the entire marketing ecosystem, where insights from one area continuously inform and enhance performance in others. That's a sweet spot for ONAR Holding Corp. (OTCQB: ONAR), a technology-first network of marketing agencies that has positioned itself nicely within this AI-driven revolution in adtech.

ONAR Holding Corp. (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

  • Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
  • Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
  • CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
  • ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

Investment Considerations
  • ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals.
  • The company is actively pursuing an acquisition-driven expansion strategy to grow its marketing agency network.
  • ONAR Labs provides a proprietary technology pipeline, offering additional revenue streams beyond traditional marketing services.
  • A strong leadership team with proven track records in business growth, financial management, and technology commercialization positions the company for long-term success.
  • ONAR’s focus on middle market and growth-stage clients aligns with sectors expected to see a sustained rise in marketing spend over the next decade.

ONAR Holding Corp. (OTCQB: ONAR), closed Thursday's trading session at $0.055, up 10%, on 18,000 volume. The average volume for the last 3 months is 1,500 and the stock's 52-week low/high is $0.03/$0.167.

Recent News

Adageis

The QualityStocks Daily Newsletter would like to spotlight Adageis

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. "One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards," reads a recent article. "Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background."

To view the full article, visit https://ibn.fm/dG4JQ

Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative solutions. By integrating artificial intelligence (AI) and machine learning, Adageis addresses inefficiencies in healthcare delivery, enabling providers to enhance patient outcomes and streamline operations. The company focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector.

With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training. This approach reduces barriers to adoption and helps healthcare organizations maximize their potential in an increasingly complex industry landscape.

Recent collaborations, including its partnership with HealthyU Clinics and integration with AthenaHealth as a marketplace partner, underscore Adageis’s industry relevance and adaptability.

Adageis is headquartered in Mesa, Arizona.

Services

Adageis offers the ProActive Care Platform, an AI-driven solution designed to integrate seamlessly with existing Electronic Medical Records (EMR) systems.

This platform enables healthcare providers to deliver patient-centric care while maximizing reimbursements from quality metrics and value-based contracts. Key features include:

  • Predictive Analytics: Utilizes AI to analyze patient data, identifying high-risk individuals and care gaps to improve health outcomes and reduce costs.
  • Efficiency and Cost Reduction: Continuously monitors patient health, allowing providers to offer proactive care even outside traditional office visits, thereby enhancing efficiency and lowering expenses.
  • Flexible Integration: Compatible with various EMR systems, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, facilitating easy adoption without the need for extensive staff training or platform changes.

Market Opportunity

The global AI in healthcare market is experiencing rapid growth, driven by the increasing demand for enhanced efficiency, accuracy, and better patient outcomes. In 2023, the market was valued at approximately $19.27 billion by Grand View Research, and it is projected to grow at a compound annual growth rate of 38.5% from 2024 to 2030. This growth is fueled by the increasing need for solutions that can analyze large datasets, reduce costs, and improve care delivery across the healthcare continuum.

Adageis is well-positioned to capitalize on these trends. Its ProActive Care Platform offers AI-driven predictive analytics and proactive care solutions that align with the industry’s shift toward value-based care. By providing seamless integration with existing EMR systems and focusing on operational efficiency, Adageis enables healthcare providers to meet the demands of a rapidly evolving market.

Leadership Team

Shane Speirs, MD, MBA serves as the company’s CEO. He is a board-certified physician in family and geriatric medicine with extensive experience in healthcare leadership, data modeling, and AI applications in healthcare delivery. He holds an MBA in Healthcare Management from the W.P. Carey School of Business and has a proven track record in managing telehealth and AI-focused healthcare companies.

Bill Jentarra, MBA is the CTO of Adageis, bringing over 25 years of experience in architecting and implementing complex client relationship management (CRM) and business intelligence (BI) solutions across various industries, including healthcare. His expertise encompasses the entire lifecycle of CRM and BI projects, ensuring practical and cost-effective technology applications to solve complex business problems.

Recent News

chart

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Amazon's CEO Andy Jassy stated in a recent memo to staff that as AI tools become more efficient, the company will likely reduce the number of traditional roles. He noted that fewer people will be needed for some current roles, while new types of jobs will open up in their place. Jassy explained that generative AI is being used extensively across Amazon's operations. From logistics to customer service, and product development to backend systems, the technology is becoming deeply embedded in nearly every area of the business. These changes reflect a growing belief among corporate leaders that AI isn't just a tool; rather, it's becoming a foundation for how modern businesses will operate, grow, and staff in the years ahead. Given the rapid pace at which tech companies like D-Wave Quantum Inc. (NYSE: QBTS) are progressing in bringing to market novel AI-powered solutions, the current estimates of the jobs likely to be lost in favor of AI could be grossly surpassed over the coming years. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Thursday's trading session at $14.06, off by 0.8462623%, on 676,290 volume. The average volume for the last 3 months is 76,615,555 and the stock's 52-week low/high is $0.7505/$19.765.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Today, more ordinary people are taking an interest in tracking their mitochondrial health in order to take concrete steps to improve their overall wellness and boost longevity. Previously, such interest was a mainstay among elite athletes, scientists and biohacking enthusiasts. Why are more people choosing to have their mitochondrial health tested? For starters, mitochondria are powerhouses inside body cells. These organelles play several vital roles, such as generating energy for cellular use, participating in the immune system's response to pathogens, contributing to cell signaling, and playing a role in programmed cell death (aka apoptosis). Mitochondrial health is therefore essential to our health and body functioning. Fortunately, some interventions, such as having a balanced diet, exercising more, tweaking your supplements regimen and managing stress, to boost metabolic health are measures that ordinary people can incorporate into their routines. When helpful steps are seen as actionable, more people are likely to be motivated to have the tests done to establish how quickly they are aging at the biological/cellular level and take steps to boost their wellbeing. For those who have been diagnosed with progressive medical conditions arising from dysfunctional mitochondria, there is hope. Recent research is uncovering ways to edit mitochondrial DNA in order to restore mitochondrial function. Furthermore, biomedical R&D programs by companies like Clene Inc. (NASDAQ: CLNN) and other entities are showing progress in developing different solutions geared at restoring mitochondrial health among individuals afflicted by ailments like Parkinson's disease, Alzheimer's and other neurological conditions. 

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $3.92, off by 4.3902%, on 56,533 volume. The average volume for the last 3 months is 136,416 and the stock's 52-week low/high is $2.2801/$7.5898.

Recent News

SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

A statement from the European Commission has revealed that the fraction of energy generated from renewable sources in the European Union registered a slight year-on-year drop from Q1 2024 to Q1 2025. According to the commission, green energy contributed to 42.5% of the EU's energy mix in the first quarter of 2025, a 4.3 percentage point drop compared to Q1 2024. Interestingly, the reduction in wind and hydro energy production was offset by a 14.1 terawatt-hour (TWh) increase in solar energy production. While both wind and hydro production declined from 260.5 TWh to 218.5 TWh between Q1 2024 and Q1 2025, these losses were counterbalanced by solar energy generation, which increased from 40.9 to 55 TWh. Denmark's renewable energy use surpassed every country in the EU, with green energy accounting for 85% of its net energy generation, while Portugal and Croatia followed at 86.6% and 77.3% respectively. Overhauling grid connection policies to eliminate these delays could unlock massive unused capacity and accelerate renewable energy deployment across the EU. Tapping into this backlog would allow member states to make better use of clean energy infrastructure that is already in place. Ultimately, removing these bottlenecks could play a key role in helping the EU reach its ambitious green energy targets and achieve energy independence.This rapid uptake of renewable energy in Europe opens significant market opportunities for enterprises like SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) that focus on manufacturing solar energy solutions for enterprise users and residential consumers.

SolarBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, SolarBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, SolarBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

SolarBank has offices in Toronto, Ontario and New York.

Projects

SolarBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, SolarBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of SolarBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, SolarBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

SolarBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

SolarBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance SolarBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, SolarBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of SolarBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of SolarBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive SolarBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by SolarBank, enhancing its asset portfolio and growth prospects.


Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

SolarBank Corp. (NASDAQ: SUUN), closed Thursday's trading session at $1.62, off by 4.7059%, on 545 volume. The average volume for the last 3 months is 544,574 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)

The QualityStocks Daily Newsletter would like to spotlight LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF).

LaFleur Minerals plans to restart its fully-permitted and recently refurbished Beacon Gold Mill in Val-d'Or, Quebec, by early 2026, offering many surrounding gold projects a much-needed nearby milling option.

In addition, a minimum 5,000-metre diamond drilling program is launching at the company's wholly-owned 166 km² Swanson Gold Project this month, and a Preliminary Economic Assessment ("PEA") is underway to evaluate open-pit mining and milling scenarios at current gold prices, as they rise above $3,300/oz, expected to hit $4,000/oz by the second quarter of 2026, JP Morgan analysts say.

In support of the company's Swanson Project plans for a 100,000-tonne bulk sample to be processed at the Beacon Mill, LaFleur expects a conservative restart cost of C$5-6 million, which includes further upgrades, benefitting from no outstanding royalties or encumbrances, providing investors both near-term production potential and exposure to the upside of surging gold, with a site visit planned for July 2025 for prospective investors and analysts.

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) a Canadian gold-focused company, has been spotlighted in a NetworkNewsWire editorial titled "Near-Term Production Assets Gain Traction amid Historic Gold Price Surge." As gold surpasses US$3,300 per ounce and bullish forecasts suggest it could reach US$4,000, LaFleur stands out with a fully permitted gold mill in Canada's top-producing region. The company offers near-term production potential and strategic exposure to the surging gold market.

To view the full press release, visit https://ibn.fm/RBC2I

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is a Canadian exploration and development company advancing the district-scale Swanson Gold Project in Québec’s prolific Abitibi Gold Belt and progressing toward the near-term restart of gold production at its wholly owned Beacon Gold Mill. The company’s strategy centers on consolidating strategic land packages—highlighted by its flagship Swanson Gold Project, a 160 km² district-scale property that includes several prospects rich in gold and critical metals previously held by Monarch Mining, Abcourt Mines, and Globex Mining. The company is leveraging its 100%-owned, fully permitted and recently refurbished Beacon Gold Mill to transition from explorer to near-term gold producer—a key inflection point that typically triggers a market re-rating, further bolstered by current rising gold market prices. By processing material from Swanson and offering custom milling to regional projects, LaFleur aims to generate cash flow with minimal capital outlay, targeting annual gold production of up to 15,000 to 20,000 ounces by early 2026.

LaFleur’s vision is to evolve into an intermediate gold producer by capitalizing on strong market conditions and Québec’s rich mining infrastructure. The location, in the world-class Abitibi Gold Belt, and its infrastructure advantage, positions LaFleur for regional consolidation, strategic partnerships, or acquisition interest. Its mission emphasizes efficient value creation through methodical exploration, low-cost asset advancement, and opportunistic acquisitions—including land and deposits from Monarch Mining, Abcourt Mines, and Globex Mining.

Québec ranks among the world’s top mining jurisdictions, offering access to flow-through capital and regulatory stability. LaFleur’s integrated strategy—combining exploration at Swanson, a permitted mill at Beacon, and potential custom milling agreements—supports a streamlined path to near-term production.

LaFleur Minerals is headquartered in Vancouver, British Columbia.

Projects

LaFleur Minerals’ operations focus on two strategically located assets in the Abitibi Gold Belt: the Swanson Gold Project and the Beacon Gold Mill and Mine. These projects leverage the region’s world-class mining infrastructure and high-grade gold potential to drive the company’s transition to production.

Swanson Gold Project

The Swanson Gold Project spans 16,600 hectares and hosts the Swanson, Bartec, and Jolin gold deposits along a major structural break in the Abitibi Gold Belt. The 2024 Mineral Resource Estimate for the Swanson deposit outlines 123,400 oz of gold in Indicated category (2.1 million tonnes at 1.8 g/t) and 64,500 oz in Inferred category (872,000 tonnes at 2.3 g/t). Located 66 km north of Val-d’Or, the Project is accessible by road and rail and benefits from more than 36,000 meters of historical drilling, along with existing infrastructure including an 80-meter decline portal.

Recent work—including airborne magnetics, soil sampling, and Induced Polarization surveys—has identified multiple high-priority targets and resulted in several high-grade gold assay results, including a grab sample grading 11.71 g/t Au at Jolin, which points to significant upside as the Company prepares to test multiple new zones.

LaFleur has defined over 50 drill targets at Swanson and nearby prospects (Bartec, Jolin, Marimac) and is completing a minimum 5,000-metre diamond drilling beginning in June 2025. LaFleur Minerals has also initiated permitting for a 100,000-tonne surface bulk sample averaging 1.89 g/t Au, which it plans to process at the Beacon Gold Mill as part of a near-term production strategy.

Beacon Gold Mill

LaFleur’s 100%-owned Beacon Gold Mill is a fully refurbished and permitted mill and tailings storage facility capable of processing 750 tonnes per day (tpd), with potential expansion to 1,800 tpd, with access to numerous nearby gold deposits that could be prime sources of ore. Located only 60 km from Swanson, it underwent a $20 million upgrade by Monarch Mining in 2022 and has been under care and maintenance since early 2023. LaFleur is finalizing a C$5-6 million restart plan, ramping up production by late 2025 into early 2026, processing Swanson mineralized material and assessing custom milling opportunities for regional deposits, creating multiple potential revenue streams.

The Beacon Gold Mill is a de-risked, proven asset that benefits from existing infrastructure, including access to roads, power, and skilled labor, and further enhances the overall value proposition of LaFleur by providing a clear path to production and potential revenue-generation.

Market Opportunity

LaFleur Minerals is targeting the gold mining and processing market in Québec’s Abitibi Gold Belt, one of the world’s most productive gold regions. Its fully permitted Beacon Gold Mill, with a 750 tpd capacity and authorization to process 1.8 million tonnes of tailings, is strategically positioned to handle material from LaFleur’s Swanson Gold Project and to offer custom milling for nearby deposits such as Granada Gold. The company projects annual production of over 30,000 ounces of gold once in full production, with potential for significant revenue generation based on prevailing market prices.

Global demand for gold remains robust, driven by geopolitical risk, inflation hedging, and central bank accumulation. The World Gold Council forecasts 3-5% annual demand growth through 2030, with average prices expected between $3,200 and $3,500/oz. Within this environment, Québec’s top-tier mining jurisdiction—ranked fifth globally by the Fraser Institute in 2023—offers streamlined permitting and access to flow-through capital. LaFleur’s low-cost Beacon restart (C$5-6 million) and proximity to more than 100 active and historical mines position the company to fill a growing need for small-to-medium scale custom milling.

At Swanson, LaFleur plans to grow its current 187,900-ounce resource toward 1 million ounces through its 2025 drilling program. This hub-and-spoke strategy, leveraging centralized milling and strong local infrastructure, reduces development risk and strengthens LaFleur’s foothold in one of the most attractive gold belts in the world.

Leadership Team

Kal Malhi, Chairman, is a successful entrepreneur and the Founder of Bullrun Capital Inc., where he has raised over $300 million for early-stage companies across the mining, oil and gas, biomedical, agriculture, and technology sectors. He specializes in advancing academic research into commercial ventures and public listings, with more than two decades of capital markets and leadership experience.

Paul Ténière, M.Sc., P.Geo., Chief Executive Officer, is a seasoned mining executive and Professional Geologist with over 25 years of global experience in the development of precious and base metals, critical minerals, and metallurgical coal projects. Mr. Ténière is an expert in NI 43-101 and S-K 1300 disclosure standards and has held senior roles including President & CEO, SVP Exploration, and Director with several publicly traded mining companies. Mr. Ténière also worked at the Toronto Stock Exchange (TSX) and TSX Venture Exchange as a mining expert and Senior Listings Manager listing dozens of mining companies and ensuring listed issuers met their corporate governance and compliance and disclosure requirements.

Harry Nijjar, Chief Financial Officer and Corporate Secretary, serves as Managing Director at Malaspina Consultants Inc., providing CFO and strategic financial advisory services to companies across multiple industries. He holds a CPA CMA designation from the Chartered Professional Accountants of British Columbia and a Bachelor of Commerce from the University of British Columbia.

Louis Martin, P.Geo., Technical Advisor and Exploration Manager, is a veteran geologist with more than 40 years of exploration experience. He has played key roles in significant gold and base metal discoveries, including the Louvicourt (1989) and West Ansil (2005) deposits—both recognized by the Association de l’Exploration Minière du Québec (AEMQ). He previously served as VP Exploration at Clifton Star Resources, where he led the pre-feasibility study for the 4.5 million-ounce Duparquet Gold Project. He is a registered geologist in Québec and Ontario.

Tara Asfour, Corporate Communications, Investor Relations and Strategy, is an experienced executive consultant with over 12 years of management, investor relations, communications and marketing experience, specialized in capital markets. In her previous positions, Ms. Asfour has led over US$550 million worth of fundraising and strategic development initiatives. Ms. Asfour holds a Master’s degree in Business Management, a Financial Markets Certificate from Yale University, and a Certificate in Alternative Investments from HBS. Previous positions include investor relations executive at Red Pine Exploration, Fancamp Exploration, Communications Director at Dominion Water Reserves (now Prime Drink Group Corp) and advisor to various other publicly listed firms in the resource and technology sectors. Ms. Asfour holds the Institute for Governance (IGOPP) Certification in Governance, Ethics in Business Environment and Corruption Prevention.

Peter Espig, Strategic Advisor and Consultant, has served as Vice-President at Goldman Sachs Japan in both the Principal Finance and Securitization Group and the Asia Special Situations Group, where his team participated in more than $10 billion in structured deals, capital raises, and cross-border transactions. Prior to Goldman Sachs, he was Vice-President at Olympus Capital, a New York-based private equity firm, where he focused on corporate restructurings, investment analysis, and international financing negotiations. He also played a pioneering role in some of the earliest SPAC transactions, totaling over US$1.2 billion, and brings deep experience in disciplined capital deployment and turnaround execution. Since 2013, Mr. Espig has served as President and CEO of Nicola Mining Inc. and is a board member of ESGold Corp and First Lithium Minerals. Mr. Espig holds a Bachelor of Arts from the University of British Columbia and an MBA from Columbia Business School, where he was a Chazen International Scholar. He has served on various public boards and was recognized among Industry Era’s “Top 10 Admired Leaders” in 2023.

Jean Lafleur, Senior Technical Advisor, is a Professional Geologist (Québec) with 45 years of experience in Canada and internationally including USA, Mexico, Latin America, Ireland, Spain and Africa. Earlier in his career he worked with Newmont, Falconbridge, Dome Mines, and Placer Dome and has been a C-suite executive for a number of junior exploration companies. Jean has remained active as a technical, management, and financing consultant with junior explorers since the early 2000’s through his own geological consultancy firm and throughout his career has led a number of teams in the discovery of precious and base metals, nickel, PGE’s, uranium, and iron deposits. Jean’s expertise includes mining company and project evaluations, audits, technical reporting, exploration program planning and execution, and research and development with a strong focus on Québec. Jean currently acts as a Senior Consultant, North America for Appian Capital Advisory LLP, a mining-focused private equity firm based in London, UK where through his extensive professional network he sources and presents potential mining transactions in North America to the Appian team for investment opportunities.

Investment Considerations
  • LaFleur Minerals’ fully permitted Beacon Gold Mill, acquired in 2024 and refurbished by its previous owner, offers a low-cost path to production with an estimated restart budget of C$5-6 million.
  • The Swanson Gold Project’s 2024 mineral resource estimate of 123,400 oz indicated and 64,500 oz inferred, alongside a 5,000-meter drilling program, supports the company’s goal of growing the resource toward 1 million ounces.
  • Consolidation of 15,290 hectares, including acquisitions from Monarch Mining, Abcourt Mines, and Globex Mining, has positioned LaFleur as a formidable exploration company in the Abitibi Gold Belt.
  • LaFleur’s hub-and-spoke development model, centered on its Beacon Mill, supports custom milling opportunities and enhances value from regional partnerships.
  • A highly experienced leadership team with over 100 years of combined expertise across mining, finance, and capital markets underpins the company’s transition from exploration to production.

LaFleur Minerals Inc. (OTCQB: LFLRF), closed Thursday's trading session at $0.319675, off by 2.2401%, on 225,437 volume. The average volume for the last 3 months is 200,820 and the stock's 52-week low/high is $0.0139/$1.65.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.